Clinical Factors Affecting Daily Dosage of Desmopressin Orally Disintegrating Tablets in Arginine Vasopressin Deficiency
Authors' conclusion
To achieve the safe and stable treatment of AVP-D, the daily dose of ODT needs to be selected based on a patient's sex, age, and eCCr under appropriate sublingual administration by patient education.
Study context
- Population
- Adults with arginine vasopressin deficiency (AVP-D) treated with desmopressin orally disintegrating tablets (ODTs) sublingually, with dose titration during hospitalization134 followed up at 1 year
- Participants
- 209 adults
- Outcome
- Clinical factors associated with daily ODT dose at discharge (multivariable linear regression)
- Follow-up
- Discharge
Methodological detailssingle-centre, Patients instructed to restrict eating and drinking for 30 min after ODT via patient leaflet, Titration with close monitoring of urine output, body weight and serum sodium
- Single-centre
- Patients instructed to restrict eating and drinking for 30 min after ODT via patient leaflet
- Titration with close monitoring of urine output, body weight and serum sodium
Main finding
As reported in the abstract
Daily dose of ODTs at discharge
Median daily dose of ODTs at discharge
90 µg
IQR 60–120 µg
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Same daily dose at 1 year after discharge (excluding patients recovering from AVP-D) | Followed up 71% |
Original publication
Clinical Factors Affecting Daily Dosage of Desmopressin Orally Disintegrating Tablets in Arginine Vasopressin Deficiency. J Clin Endocrinol Metab. Published 29 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →